Analysis of Immune Correlates Using Anti-PD-1 Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy

被引：4
|
作者：
Kim, S. [1 ]
Sanders, P. D. [1 ]
Weihe, E. [1 ]
Purcell, T. [1 ]
Kato, S. [1 ]
Patel, S. [1 ]
Kurzrock, R. [1 ]
Sharabi, A. [1 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2017年 / 99卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2017.06.2051
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3434
引用
收藏
页码：E602 / E603
页数：2
相关论文
共 50 条
  • [41] DUAL CHECKPOINT BLOCKADE USING ANTI-PD-1 AND ANTI-CTLA4 COMBINED WITH CISPLATIN CHEMOTHERAPY IS EFFECTIVE IN A MURINE MESOTHELIOMA MODEL
    Khong, Andrea
    Rozali, Esdy
    Boylen, Catherine
    Salmons, Joanne
    Robinson, Bruce
    Lesterhuis, Joost
    Lake, Richard
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S468 - S468
  • [42] Abscopal effect of stereotactic radiotherapy combined with anti-PD-1/PD-L1 immunotherapy: Mechanisms, clinical efficacy, and issues
    Zhuang, Hongqing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 649 - 654
  • [43] Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
    Zeng, Jing
    See, Alfred P.
    Phallen, Jillian
    Jackson, Christopher M.
    Belcaid, Zineb
    Ruzevick, Jacob
    Durham, Nicholas
    Meyer, Christian
    Harris, Timothy J.
    Albesiano, Emilia
    Pradilla, Gustavo
    Ford, Eric
    Wong, John
    Hammers, Hans-Joerg
    Mathios, Dimitris
    Tyler, Betty
    Brem, Henry
    Tran, Phuoc T.
    Pardoll, Drew
    Drake, Charles G.
    Lim, Michael
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (02): : 343 - 349
  • [44] Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti-PD-1 Immune Checkpoint Blockade
    Triozzi, Pierre L.
    Stirling, Elizabeth R.
    Song, Qianqian
    Westwood, Brian
    Kooshki, Mitra
    Forbes, M. Elizabeth
    Holbrook, Beth C.
    Cook, Katherine L.
    Alexander-Miller, Martha A.
    Miller, Lance D.
    Zhang, Wei
    Soto-Pantoja, David R.
    CLINICAL CANCER RESEARCH, 2022, 28 (06) : 1192 - 1202
  • [45] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [46] Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials
    Lynch, Connor
    Korpics, Mark C.
    Katipally, Rohan R.
    Wu, Tianming
    Bestvina, Christine M.
    Pitroda, Sean
    Chmura, Steven J.
    Juloori, Aditya
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1519 - 1530
  • [47] Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report
    Wu, Na
    Yang, Xiaoxin
    Zhai, Yan
    Lu, Wei
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (02) : 739 - 744
  • [48] Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
    Sibaud, Vincent
    Meyer, Nicolas
    Lamant, Laurence
    Vigarios, Emmanuelle
    Mazieres, Julien
    Delord, Jean Pierre
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) : 254 - 263
  • [49] Neuroinflammatory changes of the normal brain tissue in cured mice following combined radiation and anti-PD-1 blockade therapy for glioma
    Clausi, Mariano Guardia
    Stessin, Alexander M.
    Zhao, Zirun
    Tsirka, Stella E.
    Ryu, Samuel
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [50] Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
    Kaehler, Katharina C.
    Hassel, Jessica C.
    Heinzerling, Lucie
    Loquai, Carmen
    Moessner, Rotraut
    Ugurel, Selma
    Zimmer, Lisa
    Gutzmer, Ralf
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 (07): : 662 - 681
12345